Tesla ‘At The Top Of The EV Mountain’ – Others Are Just Now Making The Climb, Analyst Says
Tesla Inc.’s (NASDAQ: TSLA) much-awaited Investor Day proved to be a disappointment for most ob
Silvergate Capital Plagued By ‘Regulatory And Liquidity Challenges,’ JPMorgan Analyst Says
Shares of cryptocurrency-focused Silvergate Capital Corp (NYSE: SI) fell off of a cliff Thursday, plummeting 45% on its warning of a delay in its annual report and concerns over its
Why This Moderna Analyst Is Very Bullish
Shares of Moderna Inc (NASDAQ: MRNA) have lost almost 24% year to date.
While the prospects of the Covid-vaccine seem to be waning, data from the cancer vaccine is impressive, according to RBC Capital Markets.
ChatGPT Writes Palantir Analyst Note Warning Of AI Competition: Why Jim Cramer Sees It As Buy Signal For Nvidia Stock
DA Davidson initiated coverage on Palantir Technologies (NYSE:PLTR) Wednesday morning — or did they? The entire note was written by ChatGPT. The analyst firm just simply fact checked it.
Tesla Analysts Praise Vertical Integration After Investor Day, But Want More From Elon Musk: ‘Long On Vision, Short On Specifics’
Tesla Inc (NASDAQ: TSLA) held its first Investor Day on Wednesday, sharing more details about its plans for electric vehicles, increased vertical
These 5 Okta Analysts Changed Their Price Targets After FQ4 Print
Shares of Okta Inc (NASDAQ: OKTA) climbed steeply in early trading on Thursday, after the company reported an earnings beat for its fourth quarter.
7 Salesforce Analysts On Q4 Earnings: ‘Nearly Everything Investors Could Hope For’
Shares of Salesforce Inc (NYSE: CRM) were rallying Thursday morning after the company reported a fourth-quarter beat. Here's what the Street has to say.
AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says
Guggenheim initiated coverage on AbbVie Inc (NYSE:ABBV) with a Buy and a price target of $172 on diversified growth. Investors have “naturally” been…
JNJ’s Consumer Health Business Separation Will Remove Uncertainty Cloud From Company: Why This Analyst Wants Visibility
Guggenheim initiated the coverage on Johnson & Johnson (NYSE:JNJ) with a Neutral rating and a $161 price target. The analyst agrees with the…